大角嘴新盤「傲寓」首推50伙 折實價538.8萬元起
其士集團(00025.HK)與市建局合作的大角嘴住宅項目「傲寓」公布首張價單,涉及50伙單位。當中有23伙開放式及27伙一房單位,實用面積介乎262至340平方呎。
項目定價介乎597萬至797萬元,呎價介乎20,374元至25,702元。計及最高9.75%折扣優惠,折實售價介乎538.8萬至719.3萬元,折實平均呎價20,934元。
其士集團銷售及市務經理冼佩盈認為項目定價合理,相信是開心的安排。她坦言,疫情對開盤有少許影響,強調定價有顧及市場接受程度,料與市價有約10%折讓,相信具競爭力。
她又指,會留意市場反應,若熱烈的話不排除加價,計劃在周末前收票,希望能在月底開售。(jc/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.